CtrlK
BMY
NYSE
Pharmaceuticals
$55.39
USD
+$0.03 (+0.05%)
Last close
Market Cap:
$113.89B
Volume:
11.2M
Previous Close
$55.37
Day Range
$55.02 - $56.19
52 Week Range
$42.52 - $62.89
Average Volume (10 Days)
13.9M
P/E Ratio
16.14
Dividend Yield
6.60%
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
CEO
Dr. Christopher Boerner
Headquaters
Princeton, NEW JERSEY, US
Founded
1980
Employees
32,500
Bristol-Myers Squibb entered a global partnership with Hengrui Pharma valued at up to $15.2 billion, combining 13 early-stage programs across oncology, hematology, and immunology. The deal includes a $600 million upfront payment and splits global development rights, with Hengrui leading early clinical work and BMS retaining worldwide rights outside China. The collaboration aims to accelerate proof-of-concept research while diversifying both companies' pipelines.
0
0
Discover Alpha Tau Medical (DRTS) and its Alpha DaRT cancer therapy, new Tolmar deal, trial catalysts, and outlook through 2027âread now for key insights.
Bristol Myers Squibb (NYSE:BMY) is rolling out an AI driven overhaul of its procurement operations, using tools designed to shorten sourcing timelines and reshape internal buying processes. The company is also expanding its oncology footprint through a new non exclusive clinical collaboration with Arcus Biosciences that focuses on late stage cancer drug trials. These developments come alongside earlier attention on product approvals, clinical milestones, and access programs, which have...
Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.
Monte Rosa Therapeutics, Inc. is Buy-rated: molecular glue degrader biotech with Novartis/Roche partnerships and strong Phase 1 data. Click for more on GLUE.
PFE
Pfizer Inc
$23.67
-2.0%
